Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review
Novartis Unit’s Strategy Remains Unaltered As Parent Company Explores All Options
Executive Summary
Sandoz CEO Richard Saynor says the generics and biosimilars giant’s focus and strategy remain “unchanged” in the wake of a long-awaited announcement by parent company Novartis that it is exploring its options for the Sandoz business.
You may also be interested in...
$10bn Sandoz Business May Be Sold Or Spun As Novartis Weighs Options
Novartis finally has confirmed plans to begin a strategic review for its Sandoz generics and biosimilars business, following years of conjecture and suggestions from the market. However, the originator stressed that it will take its time with a decision, while underlining that keeping Sandoz is among its choices.
‘Challenging’ Times For Sandoz As COVID Bites
Sandoz saw both its sales and core operating profit experience double-digit drops in what management described as a “challenging” first quarter of 2021. However, its performance is expected to stabilize in the back end of the year as pandemic-related pressures ease.
Sandoz Aims To Be ‘First In And Last Out’ In North America
Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.